3D Mammograms Deliver Fewer False-Positive Findings However, half of women will have a false positive with annual screening with DBT Mar 25, 2022
Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer Olaparib (Lynparza) approved for high-risk patients with germline BRCA mutations Mar 14, 2022
Fluorescence-Guided Lumpectomy Shows Promise Imaging system reduced the need for re-excision in one-fifth of patients Mar 11, 2022
Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer Also: Combination targets uncommon form of advanced HER2-mutant disease Mar 09, 2022
More Options for Precision Medicine in Metastatic Triple-Negative Breast Cancer Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations Mar 08, 2022
Chipping Away at the Dogma of Axillary Dissection in Breast Cancer Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy Mar 07, 2022
Clinical Picture Brightens for HER2+ Breast Cancer With Brain Metastases New therapies breach blood-brain barrier to improve response, survival Mar 07, 2022
Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer Defining high risk, considering role of Ki-67, BRCA mutations Mar 05, 2022
Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiation Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
Black Women Most at Risk for Post-Surgical Lymphedema Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
Genomic Profiling Improves Outcomes in Breast Cancer PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
Artificial Intelligence Tool Gets High Marks in Reading Mammograms Breast cancer screening results show AI's mettle in real-world dataset Dec 02, 2021
Year in Review: HER2-Positive Breast Cancer ADCs impress in second-line therapy, primary surgery debate, neoadjuvant PD-L1 falls short Nov 15, 2021
Low-Quality Mammography Leading to More Deaths in Black Women, Says Expert In cities like Chicago, Black women face higher breast cancer mortality versus white women Oct 26, 2021
No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer Women with medially or centrally located tumors may be candidates, however, says researcher Oct 26, 2021
More Evidence for Safety of Accelerated Radiation in Early Breast Cancer Studies show low toxicity with few recurrences Oct 25, 2021
Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast Cancer Reduced risk of recurrence, distant relapse with adjuvant abemaciclib Oct 20, 2021
'Modest' Link Between Infertility and Postmenopausal Breast Cancer Study finds increased risk for younger women, those with primary infertility Oct 19, 2021
First CDK4/6 Inhibitor OK'd for Early, High-Risk Breast Cancer Abemaciclib approved with endocrine therapy for hormone receptor-positive/HER2-negative disease Oct 13, 2021
Almost Half of Breast Cancer Patients Use Cannabis, Survey Finds Common reasons for use include pain, anxiety, nausea, and insomnia Oct 12, 2021
Standard of Care Hard to Beat in HER2-Negative Breast Cancer Swapping letrozole for fulvestrant, in combination with palbociclib, did not improve PFS Oct 07, 2021
Women With Very Dense Breasts Benefit From MRI Screening Dutch researchers recommend screening with MRI every 4 years Oct 01, 2021
Different Taxanes, Similar Outcomes in Advanced HER2-Positive Breast Cancer Results from docetaxel-based study appear applicable to paclitaxel, nab-paclitaxel Sep 29, 2021
What's Behind the Racial Differences in Women's Cancer Screening? Existing medical conditions and social factors are likely driving gaps, researchers found Sep 24, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBC KEYNOTE-355 regimen offers "transformative treatment" in PD-L1-positive disease, expert says Sep 20, 2021
ADC Makes a Case for Role in Metastatic HER2-Positive Breast Cancer Improved progression-free survival in previously treated disease with trastuzumab duocarmazine Sep 20, 2021
